From what I understand, and I don't know much about it, this was intended to be a 'cheap' vaccine, so a cash grab seems unlikely. Given that the elderly are most at risk, and the risk of blood clots is mostly in younger people, it seems that it can serve a useful function - regardless of its limitations.
At least you realize it when your ideas are tinfoil according to others.
These vaccines are intended to usher in a subscription model. They have limited long-term efficacy and only protect you from a very narrow range of variants. You will require frequent and neverending booster shots to protect you from the cold and flu each year. Now that vaccine manufacturers have got their foot in the door, they can hold society hostage every 6-12 months.
IIRC, it's extremely ineffective against most variants. Especially P.1 Brazil variant and South African variant B.1.1.3(?)
My most sane answer to your question is that it's a cynical cash grab, while my actual belief is pretty far in the tinfoil.
From what I understand, and I don't know much about it, this was intended to be a 'cheap' vaccine, so a cash grab seems unlikely. Given that the elderly are most at risk, and the risk of blood clots is mostly in younger people, it seems that it can serve a useful function - regardless of its limitations.
At least you realize it when your ideas are tinfoil according to others.
These vaccines are intended to usher in a subscription model. They have limited long-term efficacy and only protect you from a very narrow range of variants. You will require frequent and neverending booster shots to protect you from the cold and flu each year. Now that vaccine manufacturers have got their foot in the door, they can hold society hostage every 6-12 months.
I mean, she's planning to start her own vaccine company and they're doing an IPO soon. The cash grab angle seems to fit.
I never disputed it, but unlike most tinfoil people, I seem to be right on my ideas, even if the extent wasn't right.
Releasing a vaccine that is dangerous isn't going to do anything good for an IPO.
Confirmation bias and special pleading go a long way.
Unless the IPO is bought up by allies of the cause. I heard Goolag is buying in.
Any vaccine could be the one that turned out fatal, but it turned out to be the one made by a woman. I count that as a win for my idea.